REGN - Regeneron Pharmaceuticals, Inc.
NEXT EARNINGS:
Apr 30, 2026
EPS Est: $9.16
|
Rev Est: $3.5B
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$857.17
DETAILS
HIGH:
$1057.00
LOW:
$700.00
MEDIAN:
$867.50
CONSENSUS:
$857.17
UPSIDE:
11.01%
Market Cap:
80.23B
Volume:
628,658
Avg Volume:
878,786
52 Week Range:
476.49-821.11
Sector:
Healthcare
Industry:
Biotechnology
Beta:
0.41
Last Dividend:
$3.58
Exchange:
NASDAQ
Country:
US
Employees:
15,158
IPO Date:
1991-04-02
EPS (TTM):
43.07
P/E Ratio:
17.92
Revenue (TTM):
14.34B
Total Assets:
40.56B
Total Debt:
2.71B
Cash & Equiv:
3.12B
Rev Growth (5Y):
11.0%
EPS Growth (5Y):
5.7%
FCF Growth (5Y):
15.3%
ROCE:
14.6%
Debt/Equity:
0.09
Earnings History
| Date | EPS Actual | EPS Est | EPS Surprise | Rev Actual | Rev Est | Rev Surprise |
|---|---|---|---|---|---|---|
| 2026-01-30 | $11.44 | $10.74 | +6.5% | $3.9B | $3.8B | +1.9% |
| 2025-10-28 | $11.83 | $9.65 | +22.6% | $3.8B | $3.6B | +4.5% |
| 2025-08-01 | $12.89 | $8.43 | +52.9% | $3.7B | $3.3B | +11.8% |
| 2025-04-29 | $8.22 | $8.62 | -4.6% | $3.0B | $3.2B | -6.8% |
| 2025-02-04 | $12.07 | $11.21 | +7.7% | $3.8B | $3.7B | +1.3% |
| 2024-10-31 | $12.46 | $11.69 | +6.6% | $3.7B | $3.7B | +1.2% |
| 2024-08-01 | $11.56 | $10.61 | +9.0% | $3.5B | $3.4B | +4.8% |
| 2024-05-02 | $9.55 | $10.17 | -6.1% | $3.1B | $3.2B | -2.5% |
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 14.34B | 14.20B | 13.12B | 12.17B | 16.07B | 8.50B | 6.56B | 6.71B | 5.87B | 4.86B | 4.10B | 2.82B |
| Net Income | 4.50B | 4.41B | 3.95B | 4.34B | 8.08B | 3.51B | 2.12B | 2.44B | 1.20B | 895.52M | 636.06M | 348.07M |
| EPS | 43.07 | 40.90 | 37.05 | 40.51 | 76.40 | 32.65 | 19.38 | 21.29 | 11.27 | 8.55 | 6.17 | 3.36 |
| Total Assets | 40.56B | 37.76B | 33.08B | 29.21B | 25.43B | 17.16B | 14.81B | 11.73B | 8.76B | 6.97B | 5.61B | 3.87B |
| Total Debt | 2.71B | 2.70B | 2.70B | 2.70B | 2.70B | 2.70B | 713.90M | 708.50M | 703.45M | 481.13M | 375.51M | 459.06M |
| Cash & Equivalents | 3.12B | 2.49B | 2.73B | 3.11B | 2.89B | 2.19B | 1.62B | 1.47B | 812.73M | 535.20M | 809.10M | 648.72M |
| Operating Cash Flow | 4.98B | 4.42B | 4.59B | 5.01B | 7.08B | 2.62B | 2.43B | 2.20B | 1.31B | 1.49B | 1.33B | 752.43M |
| Free Cash Flow | 4.08B | 3.66B | 3.67B | 4.42B | 6.53B | 2.00B | 2.00B | 1.81B | 1.03B | 974.00M | 652.85M | 419.43M |
| FCF per Share | 39.01 | 33.96 | 34.37 | 41.31 | 61.77 | 18.62 | 18.32 | 15.78 | 8.93 | 8.38 | 5.67 | 3.70 |
| Book Value | 31.26B | 29.35B | 25.97B | 22.66B | 18.77B | 11.03B | 11.09B | 8.76B | 6.14B | 4.45B | 3.65B | 2.54B |
| Cash & ST Investments | 8.61B | 9.01B | 10.84B | 7.74B | 5.69B | 3.59B | 3.21B | 2.81B | 1.41B | 1.04B | 1.05B | 900.48M |
| ROC Equity | 0.14 | 0.15 | 0.15 | 0.19 | 0.43 | 0.32 | 0.19 | 0.28 | 0.20 | 0.20 | 0.17 | 0.14 |